Lundbeck Explores Acquisition of Xeris
Danish drugmaker H Lundbeck has expressed interest in acquiring Xeris Biopharma according to recent reports. Xeris declined to comment on the potential takeover discussions. The company currently develops therapies for endocrine and rare neuromuscular conditions.
Xurve View
Insights:
Xurve View
H LUNDBECK A/S-A SHS has explored a potential acquisition of XERIS BIOPHARMA HOLDINGS INC following discussions led by external advisers. The approach highlights strategic consolidation trends across the pharmaceutical sector. Any completed transaction would require a substantial premium over Xeris's current trading price of ~$10 per share.
